Literature DB >> 20138585

C-reactive protein in myocardial infarction binds to circulating microparticles but is not associated with complement activation.

P M van der Zee1, E Biró, L A Trouw, Y Ko, R J de Winter, C E Hack, A Sturk, R Nieuwland.   

Abstract

BACKGROUND: C-reactive protein (CRP) is elevated in patients with acute myocardial infarction (AMI). When CRP binds to membrane phospholipids or Fc receptors, it activates the complement system. Recent studies show that CRP can be exposed on cell-derived microparticles (MP) and is associated complement activation.
OBJECTIVES: We studied complement activation on circulating MP in AMI patients and healthy controls.
METHODS: MP were isolated from plasma of AMI patients (n=21) and sex- and age-matched healthy individuals (n=10), and analyzed by flow cytometry for bound complement components (C1q, C4, C3) and complement inhibitor and activator molecules (C4bp, CRP, serum amyloid P component, immunoglobulins IgM and IgG). Concurrently, the levels of fluid phase complement activation products and inhibitor and activator molecules were determined.
RESULTS: Fluid phase CRP, MP with bound CRP (CRP + MP), and C3 activation products were elevated in AMI patients compared to controls (P=0.032, P=0.031 and P=0.023, respectively), and fluid phase CRP correlated with CRP+ MP (r=0.84, P<0.001). Although CRP+ MP were elevated, they were not associated with C1q+ MP (r=0.32, P=0.174). In contrast, IgG+ MP were associated with C1q+ MP (r=0.73, P<0.001), C4+ MP and C3+ MP (r=0.78 and r=0.87, respectively; both P<0.001), and C4bp (r=0.63, P=0.004). In healthy individuals, CRP+ MP were strongly associated with C1q+ MP (r=0.82, P=0.007), which in turn were associated with C4+ MP and C3+ MP (r=0.68, P=0.032 and r=0.68, P=0.031, respectively).
CONCLUSIONS: Despite CRP-associated complement activation on the surface of MP in healthy individuals and a strong correlation between MP-bound CRP and fluid phase CRP in AMI patients, the MP-associated complement activation is IgG- but not CRP-dependent in AMI patients. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138585     DOI: 10.1016/j.clim.2010.01.002

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  7 in total

1.  C-reactive protein (CRP) aptamer binds to monomeric but not pentameric form of CRP.

Authors:  Min S Wang; Joshua C Black; Michelle K Knowles; Scott M Reed
Journal:  Anal Bioanal Chem       Date:  2011-07-02       Impact factor: 4.142

2.  Direct visualization of electrophoretic mobility shift assays using nanoparticle-aptamer conjugates.

Authors:  Min S Wang; Scott M Reed
Journal:  Electrophoresis       Date:  2011-12-14       Impact factor: 3.535

3.  Inflammation, a link between obesity and cardiovascular disease.

Authors:  Zhaoxia Wang; Tomohiro Nakayama
Journal:  Mediators Inflamm       Date:  2010-08-05       Impact factor: 4.711

4.  Cause or effect of arteriogenesis: compositional alterations of microparticles from CAD patients undergoing external counterpulsation therapy.

Authors:  Ali Al Kaabi; Tobias Traupe; Monika Stutz; Natasha Buchs; Manfred Heller
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

5.  Microparticles as novel biomarkers and therapeutic targets in coronary heart disease.

Authors:  Bo-Da Zhou; Ge Guo; Le-Min Zheng; Ling-Yun Zu; Wei Gao
Journal:  Chin Med J (Engl)       Date:  2015-01-20       Impact factor: 2.628

6.  Extracellular vesicles are associated with C-reactive protein in sepsis.

Authors:  Birgit Fendl; René Weiss; Tanja Eichhorn; Ingrid Linsberger; Taras Afonyushkin; Florian Puhm; Christoph J Binder; Michael B Fischer; Viktoria Weber
Journal:  Sci Rep       Date:  2021-03-26       Impact factor: 4.379

7.  Improved flow cytometric assessment reveals distinct microvesicle (cell-derived microparticle) signatures in joint diseases.

Authors:  Bence György; Tamás G Szabó; Lilla Turiák; Matthew Wright; Petra Herczeg; Zsigmond Lédeczi; Agnes Kittel; Anna Polgár; Kálmán Tóth; Beáta Dérfalvi; Gergő Zelenák; István Böröcz; Bob Carr; György Nagy; Károly Vékey; Steffen Gay; András Falus; Edit I Buzás
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.